Scipher Medicine, a company focused on proprietary AI and network biology platform solutions to transform patient care, has launched a new approach to develop biomarkers following the publication of t...
Autore: Business Wire
WALTHAM, Mass.: Scipher Medicine, a company focused on proprietary AI and network biology platform solutions to transform patient care, has launched a new approach to develop biomarkers following the publication of the novel, patent-pending framework PRoBeNet (Predictive Response Biomarkers using Network medicine).
“I am thrilled to be launching PRoBeNet to enable an accelerated path for early biomarker development in complex diseases,” said Reg Seeto, MBBS, President and CEO. “This product further expands our portfolio of offerings within companion and complementary diagnostics which have utility in late stage drug development, precision medicine, and, ultimately, improve patient outcomes.”
PRoBeNet addresses the ongoing challenge with precision medicine’s ability to transform complex autoimmune-disease treatment. The key development challenges to accelerated biomarker development are limited data availability and small sample sizes. Scipher’s novel framework solution addresses these issues using AI and network biology to identify biomarkers of therapy response with inputs from therapy-targeted proteins and disease-specific molecular signatures with our human interactome, which is an underlying network of interactions among cellular components.
PRoBeNet has now been validated across a spectrum of autoimmune disease states including rheumatoid arthritis, ulcerative colitis and Crohn’s disease, with an approved and investigational drug. PRoBeNet can also be generalized to other complex diseases, and drugs in different phases of development if the treatment-targeted proteins and appropriate disease-signature molecules are known.
About Scipher Medicine
Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, believes that patients deserve simple answers to treatment options based on scientific data. Using Spectra™, a proprietary network medicine platform, Scipher commercializes tests revealing a person’s unique molecular disease signature and match it to the most effective therapy, ensuring optimal treatment from day one. The patient molecular data generated from our tests further supports the discovery and development of novel and more effective therapeutics. Scipher partners with leading payers, healthcare providers, and pharmaceutical companies to bring solutions to patients across diseases. To learn more about Scipher visit sciphermedicine.com and follow Scipher Medicine on Facebook, X, and LinkedIn.
Fonte: Business Wire